

Drug Monograph

Drug Name: **Nix Ultra® (mineral oil/dimethicone) solution**
 Drug Class: **Dermatologic Agents: Topical Antiparasitics, Treatment of Lice and Scabies**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Nix Ultra is available in a 100 ml bottle of 1% solution.

Manufacturer: Distributed by: Prestige Consumer Healthcare Inc., Lynchburg, VA 24502.

Indications: Nix Ultra is indicated for elimination of lice by suffocation. It is specifically designed to eliminate hard-to-kill Super Lice, which have developed resistance to many traditional lice treatments.

Costs: \$14 per 100 ml bottle of 1% solution. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD

Date: September 13, 2021